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 ABSTRACT 
Orellanine is a fungal nephrotoxin selectively toxic to the human tubular 
epithelial cells (HTEC) of the kidney nephrons leading to kidney failure. 
Patients treated with renal replacement therapy after orellanine poisoning 
show no signs of damage to other organs in the body. 
 
Aims: Our main aim in this thesis is to develop chronic peritoneal dialysis 
(PD) in anuric rodents, to better understand the pharmacokinetic properties of 
orellanine and to evaluate orellanine as an experimental treatment against 
metastasized clear cell renal cell carcinoma (ccRCC). 
 
Methods: The first paper is an in vivo study of chronic automated PD in  
anuric rats. Orellanine was used to induce uremia. Blood, dialysis fluid, and 
tissue samples were examined for electrolyte profiles, inflammatory status, 
and morphology. The second paper is an in vivo study in which rats were 
given intravenous injections of labeled/unlabeled orellanine. The distribution 
of orellanine was imaged, and orellanine plasma concentrations were 
measured over different time points. The third paper had two parts: an in 
vitro part examining the effect of orellanine on HTEC, epithelial cells, 
ccRCC cells, and other cancer cell lines, and an in vivo part with a xenograft 
rat model testing the effect of orellanine on metastasized ccRCC tumors.  
 
Results: The levels of urea and creatinine in orellanine-treated rats indicated 
severe uremia. The automated PD system developed in our lab provided 
adequate dialysis. The rats gained weight and had normal homeostasis. 
Orellanine was cleared renally and was mainly distributed to the renal cortex 
and the urinary bladder. Orellanine induced necrosis, apoptosis, and 
disruption of cellular functions and growth on HTEC and ccRCC cells while 
having no significant effect on other tested cell lines at the same doses. 
Finally, orellanine induced significant apoptosis and necrosis in the 
xenografted tumors in vivo. 
 
Conclusions: Orellanine selectively causes renal failure, which is irreversible 
at high doses.  We describe the first successful treatment of rats with severe 
uremia that, despite anuria, were kept healthy over a period of at least 21 
days. The system can be used to improve PD and to study various aspects of 
uremia. The pharmacokinetic properties of orellanine were investigated and it 
was shown that orellanine is distributed mainly to the urinary system. 
Orellanine induced significant apoptosis and necrosis in metastasized 
xenografted tumors in vivo and showed no signs of affecting other organs. 
Therefore, we suggest that its therapeutic effects should be further examined 
as a treatment option for late stage ccRCC patients.  
 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Orellanin är ett svampgift som återfinns i vissa arter av släktet Cortinarius 
som exempelvis toppig giftspindling. Patienter som uppsöker sjukhus på 
grund av att oavsiktligt ha misstagit svamparna för ätliga uppvisar 
dosberoende skador på njurarna och kan komma att behöva dialys eller 
njurtransplantation för att överleva.  De patienter som drabbats av 
orellaninförgiftning uppvisar inga skador på andra organ i kroppen vilket 
visar att giftet är njurspecifikt. De celler i njuren som orellanin dödar är också 
de celler som ger upphov till klarcellig njurcancer, de proximala 
tubulicellerna.  
Ca 600 personer om året drabbas av njurcancer i Sverige och hälften av dem 
dör av sin cancer. Den vanligaste och dödligaste typen av njurcancer heter 
klarcellig njurcancer vilken oftast drabbar den ena njuren och om den inte har 
spridit sig kan tumören avlägsnas kirurgiskt. Tyvärr upptäcker man oftast 
denna typ av cancer när tumören redan har bildat dottertumörer i kroppens 
andra organ som hjärnan, benmärgen eller lungorna. Femårsöverlevnaden för 
spridd klarcellig cancer uppgår till ca 10%. I dagsläget finns det ingen 
botande behandling att tillgå. 
Då orellanin dödar de celler som cancern utvecklas från är vår hypotes att 
orellanin skulle kunna utgöra behandling för spridd klarcellig njurcancer. För 
att kunna testa vår hypotes behövde vi först utveckla en bra metod för dialys 
på djur, då orellaninbehandling kommer skada njurarna. Dessutom ville vi 
studera om orellanin kan användas i en sådan dialysmodell för att introducera 
njurskada utan att behöva använda kirurgiska metoder. Vidare behövde vi 
bättre förstå orellaninets egenskaper samt distribution i kroppen innan 
slutligen orellanins effekt på klarcellig njurcancer kunde studeras. 
Idag finns det cirka 9000 patienter Sverige som genomgår dialys eller har fått 
en ny njure på grund av nedsatt njurfunktion. Det finns två typer av dialys; 
bloddialys (HD) och peritonealdialys (PD). Vid bloddialys renas blodet 
utanför kroppen i en dialysmaskin och kräver att patienten är uppkopplad till 
denna maskin flera timmar i veckan. PD fungerar genom att man injicerar 
dialysvätska in i buken på patienten och denna vätska som via bukhinnan tar 
upp slaggprodukter och vatten till dialysvätskan. Under tiden som 
dialysvätskan är i buken är patienten inte bunden till några maskiner och får 
bättre livskvalité. Tyvärr kan bara ungefär 10 % av patienterna fortsätta med 
PD efter en sjuårsperiod då bukhinnan förtjockas, kan drabbas av upprepad 
inflammation och därför få en sämre funktion med tiden. Det finns därför ett 
 stort behov av utveckla metoder och dialysvätskor för peritoneladialys 
ytterligare. För att efterlikna PD hos människa utvecklade vi ett system där 
råttor utan njurfunktion dialyserades i 21 dagar. Effektiviteten och graden av 
inflammation undersöktes och vi fann att vår modell var mycket effektiv och 
kan användas för framtida studier kring PDs effekter på bukhinnan för att på 
så sätt förbättra situationen för patienter som erhåller peritonealdialys.  
För att få veta hur länge orellanin stannar kvar i kroppen undersökte vi 
orellanins halveringstid i cirkulationen samt om dialys kan rena bort 
orellanin. Vi fann att orellanin har en halveringstid på strax under två timmar 
och att dialys kan rena bort orellanin från kroppen men att det tar längre tid 
än njurarnas eliminering av orellanin. Studier av orellanins distribution i 
kroppen hos råttor visade att de organ där orellanin mest ansamlades som 
väntat var njuren och urinblåsan.  
I det tredje arbetet i avhandlingen undersökte vi orellanins effekt på tubulära 
njurceller samt på njurcancerceller. Vi jämförde effekten på 
njurcancercellerna och njurcellerna med celltyper från andra delar av 
kroppen. Våra resultat visade att orellanin hade en selektiv effekt på 
njurceller och njurcancerceller men inte på andra celltyper.  
Nästa steg i att testa orellanins effekt på spridd klarcellig njurcancer var att 
testa behandlingen på djur. Vi inplanterade humana celler från en klarcellig 
cancermetastas i råttor och efter att tumören växt till startades 
orellaninbehandling. Dialysuppställningen från delarbete 1 användes för att 
ersätta njurfunktionen under behandlingen. 
Resultatet var att svampgiftet minskade de inplanterade tumörmassorna 
signifikant och effekten på andra organ var minimal. Celldöden i de 
behandlade tumörerna var utbredd. Tumörmassan blev drastiskt och 
signifikant mindre i omkrets, vikt och antalet levande celler var kraftigt 
reducerat efter behandling. 
Sammantaget har orellanin visat potential för att kunna vara ett framtida 
behandlingsalternativ för klarcellig njurcancer och vi har fått fler, nya sätt att 
studera hur dialys påverkar kroppen och hur vi kan förbättra nuvarande 
dialysprotokoll. 
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 1 
1 INTRODUCTION 
In 1952 in Poland, 102 patients became ill after ingesting wild mushrooms 
and developed kidney failure. This incident led to the discovery of the 
mushroom toxin orellanine, found in species of the Cortinarius family (1). 
Orellanine was found to primarily target the proximal convoluted tubular 
cells in the kidney (2-4). Patients that develop kidney failure due to orellanine 
poisoning and then receive renal replacement therapy (RRT) have shown no 
damage to any organs other than the kidneys (5).  
In this thesis, we investigated the use of orellanine in peritoneal dialysis (PD) 
experimental research. Orellanine was utilized as a chemical nephrectomy 
tool in inducing renal failure in an in vivo chronic PD model developed in our 
lab.  
Since clear cell renal cell carcinoma (ccRCC) develops from the same cells 
that are the target for orellanine (6), the therapeutic potential of this 
nephrotoxin against ccRCC was tested (7). Before using orellanine as a drug 
in research or therapeutically, the pharmacokinetics and distribution of 
orellanine were examined (8).   
 
1.1 THE KIDNEY 
The kidneys are retroperitoneally located organs in the abdomen, 
anatomically divided into a thin capsule, the cortex, and the medulla. The 
medulla tapers off into papillae that point toward the calyces that pour urine 
into the renal pelvis. The ureter transports urine from the renal pelvis down to 
the urinary bladder. Renal blood supply is maintained through the renal 
artery, which branches from the abdominal aorta. The renal venous return is 
through the renal vein, carrying blood back to the inferior vena cava. The 
kidneys have sympathetic and parasympathetic innervation via the renal 
plexus that runs alongside the renal artery (9, 10).  
The function of the kidneys is to maintain the water balance in the body, 
keeping the electrolyte balance and the excretion of toxic waste products 
from the body in check. The kidneys also function as an endocrine organ, 
secreting active vitamin D, renin, and erythropoietin (11). 
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1.1.1 The nephron 
The nephron is the functional unit of the kidney (see Figure 1). There are 
approximately one million nephrons per kidney. The nephron is divided into 
different segments: the glomerulus, the proximal convoluted tubule (PCT) 
segment, the loop of Henle, the distal convoluted tubular segment (DCT), and 
the collecting duct. The glomerulus has a capsule (Bowman’s capsule) that is 
connected to the PCT and surrounds the glomerular capillary network. This 
network starts with the afferent arteriole and ends with the efferent arteriole 
that exits the capsule. The latter continues as the peritubular capillary 
network that surrounds the different segments of the nephrons, returning 
reabsorbed solutes and water to the circulation. The glomerulus is the main 
connection between the nephron and the circulatory system. Solute and water 
are filtered over the capillary wall of the glomerulus and collected in 
Bowman’s capsule, forming the primary urine that continues through the 
PCT, loop of Henle, DCT, and then the collecting duct. Several collecting 
ducts drain urine into the calyces and then to the ureter and urinary bladder. 
Specialized epithelial cells line the tubular sections and different segments 
have different functions in terms of secretion and reabsorption of solutes and 
water. Each segment of a nephron is anatomically divided into a luminal 
brush border, a cellular part, and a basolateral border. The luminal side faces 
the tubular lumen of the nephron tubules. The cellular part refers to the cells 
comprising the nephron tubule for each segment. The basolateral side marks 
the contact of the tubular cells with the blood in the peritubular capillary 
network. Two types of nephrons are found in the kidneys: the cortical 
nephrons, which are characterized by short tubular segments, and the 
juxtaglomerular nephrons. The juxtaglomerular nephrons have their 
Bowman’s capsules in the inner cortex, with tubular loops that are long 
enough to reach the papillary area. Juxtaglomerular nephrons are important 
for concentrating the urine (11, 12). 
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Figure 1. The nephron. Modified from Ebefors and Nyström, New insights into cross-talk 
in the kidney, Current Opinion in Nephrology and Hypertension (13) 
 
1.1.1.1 The glomerulus   
The first part of the nephron is the glomerulus, which is a capillary tuft 
forming the filtration barrier of the kidney. The hydrostatic pressure in the 
glomerulus is approximately 55 mmHg, compared to 18 mmHg in other 
capillary beds, enabling filtration over the capillary wall (glomerular 
filtration membrane). Small molecules like water and glucose pass freely 
through the membrane, whereas larger molecules pass with greater difficulty. 
This mechanism keeps the plasma proteins on the blood side and reduces 
water loss due to higher oncotic pressure in the blood (14). The inner layer of 
the filtration barrier, facing the blood compartment, is the endothelial cell 
surface layer covering the endothelium. The endothelial cell surface layer 
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consists of secreted and anchored proteins forming a gel-like structure 
covering the cell surface. The endothelial surface layer has long been debated 
mainly due to its complex structure and difficulty to visualize. However, 
there is a growing interest in research toward understanding the role of this 
layer and its contribution to the permselectivity of the glomerular filtration 
barrier (15, 16). The endothelial cells are heavily fenestrated with fenestrae of 
approximately 70–100 nm in diameter, covered by the cell coat (17). The 
second layer is the basement membrane. This layer is further divided into 
lamina rara externa, densa, and interna. The basement membrane is an 
acellular, extracellular matrix layer and accounts for approximately 50% of 
the hydraulic resistance (fluid restriction) of the glomerular barrier. It is 
composed of type IV collagen, laminins, nidogens, and proteoglycans (18). 
The third layer of the glomerular filtration barrier is composed of highly 
specialized epithelial cells called podocytes. These cells have a specialized 
morphology with foot processes, connecting neighboring cells with junctions 
that form filtration slit pores that are 25–55 nm in diameter. The slit pores are 
also termed slit diaphragms. They are highly important for the pemselectivity 
of the glomerular barrier (19, 20). All layers of the glomerular barrier are 
negatively charged. The negative charges are usually made up by sulfated 
side chains of structural proteins such as proteoglycans and collagens. These 
negative charges are known to repel the negatively charged plasma proteins 
in the blood and this is thought to make up a significant part of the 
permselective properties of the barrier. The barrier is generally considered to 
be size-, charge-, and to a certain extent, shape-restricting. This means that a 
small, neutral, and elongated molecule more easily passes the membrane 
compared to a large, negatively charged, and bulky molecule (21). Once the 
fluid with smaller solutes is filtered over the filtration barrier into Bowman’s 
capsule, it is called ultrafiltrate, containing all the solutes dissolved into the 
blood except for blood cells, proteins, and solutes bound to plasma proteins. 
Therefore, the ultrafiltrate is very similar in composition to the interstitial 
fluid.  
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1.1.1.2 The tubular system 
The first part of the tubules to receive the ultrafiltrate from the Bowman’s 
capsule is the PCT. This section is approximately 15 mm long. The next 
section is the loop of Henle, which is similar in length. The DCT is shorter 
than the PCT. Four processes govern the flow of solutes and water and lead 
to the formation of the final urine. Filtration is the flow of fluid from the 
glomerular capillary network into the Bowman’s capsule, thus producing the 
glomerular ultrafiltrate. Reabsorption is the flow of fluid back from the 
tubular lumen to the peritubular capillary network. Secretion is the flow of 
fluid and solutes out from the peritubular capillary network into the lumen of 
the tubuli. Excretion is the flow of urine out of the collecting duct and into 
the renal pelvis. Except for the descending thick limb of the loop of Henle, all 
the other nephron parts have a Na+-K+ ATPase pump on the basolateral side. 
This pump generates a sodium concentration gradient leading to reabsorption 
of solutes from various channels, co-transporters, and anti-transporters on the 
luminal side (11). 
The PCT segment reabsorbs two-thirds of the total water and solute in the 
ultrafiltrate from the Bowman’s capsule. This segment plays a prominent role 
in the reabsorption of the filtered solutes such as electrolytes, amino acids, 
and glucose. PCT cells are equipped with large numbers of mitochondria, 
making up approximately 40% of the volume of these cells (22), which is due 
to the high energy requirement of these cells and their abundant basolateral 
Na+-K+ ATPase pumps. The PCT segment is histologically subdivided into 
early PCT and late PCT sections. The early PCT section has a large number 
of co-transporters: Na+-glucose, Na+-amino acid, Na+-phosphate, lactate or 
citrate co-transport, as well as the Na+- H+ exchanger on the luminal border. 
Except for the Na+-K+ ATPase that forces sodium into the blood against its 
electrochemical gradient, all other solutes exit the early PCT into the blood 
by facilitated diffusion. Na+-K+ ATPase is vital in ensuring the concentration 
gradient for maintaining the reabsorption of all the co-transported molecules 
across the luminal side of the PCT cells (23). The late PCT section has Na+- 
H+ exchangers and Cl--formate anion exchangers, leading to the reabsorption 
of NaCl from the lumen into the cells. Then, Na+-K+ ATPase drives sodium 
back to the blood while chloride is reabsorbed by simple diffusion. Several 
transporters for drugs and xenobiotics are found in the PCT cells. The 
majority either belong to the ATP-binding cassette transporters (ABC) 
superfamily or the solute carrier transporters gene superfamily (SLC) (24, 
25). The organic anion transporter (OAT) family belongs to the SLC 
superfamily and is responsible for handling organic anionic substances like 
drugs and metabolites. The main OATs in the kidneys are OAT1, 2, 3, 4, 5, 8, 
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and 10. Both the luminal and the basolateral sides of the epithelial cells of the 
PCT have these transporters. The OAT substrates are a variety of xenobiotics, 
drugs, and metabolites. Some of these substrates are antibiotics, antivirals, 
antihypertensive drugs, diuretics, H2-antagonists, non-steroidal anti-
inflammatory drugs, statins, and uricosurics (26, 27).  
Human multidrug resistant proteins (hMRPs) are ATP-dependent efflux 
transporters that belong to the ABC superfamily and are located on the brush 
border side (MRP2 and MRP4) and the basolateral side (MRP6) of the PCT 
cells. These OATs handle the excretion of anti-cancer drugs, cAMP, cGMP, 
and urate into the urine (28). Organic cation transporters (OCTs) are also 
members of the SLC family. OCT1 is present on the brush border side and 
OCT2 on the basolateral side of the PCT cells (29). The substrates for these 
transporters are tetraethylammonium, 1-methyl-4-phenylpyridimium, 
endogenous monoamines, the antidiabetic drug metformin, the 
antihypertensive drug atenolol, the antiviral drug lamivudine, and the 
cytostatic drug oxaliplatin (30).  
Multidrug and toxin extrusion (MATE) transporters are H+/organic cation 
antiports (31). MATE1 and MATE2-k are located on the luminal brush 
border of the PTC cells (32). They extrude organic cations taken up by the 
OCTs. Other transporters of the PCT cells are the P-glycoprotein (P-gp) 
transporters. P-gp transporters are OCTs of the ABC superfamily and are 
found on the luminal border of the PCT. They are involved in the excretion 
of steroids and drugs into the urine (33, 34). Some of these transporters are 
more likely than others to be responsible for the uptake of orellanine (the 
nephrotoxin studied in this thesis) into the PCTs, but it is yet not known what 
causes a selective uptake of orellanine into the PCTs.  
Collectively, the loop of Henle, the DCT, and the collecting duct reabsorb 
approximately 20–30% of the total solute and 15–20% of water. The loop of 
Henle is divided into the descending limb and the ascending limb. The 
descending limb does not allow reabsorption or secretion of solutes but is 
permeable to water. The opposite is true for the ascending limb. By the time 
the ultrafiltrate reaches the DCT, it contains approximately 10% of the 
originally filtered NaCl and 25% of the water. The DCT and the collecting 
duct reabsorption process are mainly regulated by hormones in response to 
the body’s need for water, sodium, and calcium. Aldosterone regulates Na+ 
reabsorption, anti-diuretic hormone regulates water reabsorption, and 
parathyroid hormone regulates Ca2+ reabsorption (11). 
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1.1.2 Water balance  
Approximately 60% of human body weight is water, dividable in two major 
compartments: the intracellular fluid (ICF) compartment, having two-thirds 
of the body’s water volume, and the extracellular fluid (ECF) compartment, 
containing the remaining third. The extracellular compartments are further 
subdivided into the intravascular compartment, comprising one fourth of the 
total extracellular water in the plasma, whereas the remaining three-fourths 
are in the interstitial extracellular compartment. Once the physiological 
electrolyte balance is disturbed, or when a certain compartment experiences a 
gain or loss of fluid, water shifts between the different compartments (35). 
The ICF compartment is the water inside the cells and its main solutes are the 
cations potassium (K+) and magnesium (Mg2+). The major anions in ICF are 
proteins and organic phosphates. The main cation in the ECF compartment is 
sodium (Na+) and the major anions are chloride (Cl−) and bicarbonate (HCO3-
) (36).  Alongside the proteins, the concentrations of these electrolytes dictate 
the tonicity of the different water compartments and thereby water volume 
ratios (37). The kidneys play a crucial role in keeping the homeostasis and 
the ratios in the fluid compartments of the body under control (11). Any 
disturbances in the balance of fluid distribution can lead to dramatic 
consequences on blood pressure, cardiac output, overall PH, and electrolyte 
profiles in and out of the cells of the body (38). 
 
1.1.3 Renal clearance 
The term renal clearance describes the rate at which a substance is removed 
from the body by renal excretion. This is stated as volume of plasma cleared 
of a substance per unit of time. The equation for clearance is the 
concentration of a substance in urine multiplied by the urine flow divided by 
the concentration of the substance in the plasma. The higher the clearance of 
a substance, the more plasma volume is cleared of that substance per unit 
time (39). 
Inulin and organic acids are freely filtered through the glomerular membrane, 
while albumin is too large to pass the glomerular filtration barrier. Inulin is a 
small inert molecule that is filtered at the same rate as small solutes such as 
glucose and ions. However, glucose, sodium, urea, and other molecules 
cannot be used to measure clearance, as they are reabsorbed. One way to 
measure kidney function is by measuring the glomerular filtration rate 
(GFR), which is the flow of plasma from the glomerulus into Bowman’s 
capsule over a defined period of time (40). Inulin is neither reabsorbed nor 
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secreted and therefore is a good molecule to use for measuring the GFR (41). 
A similar substance to inulin is endogenous creatinine. In clinical practice, 
creatinine is more commonly used to estimate the GFR than inulin. 
Creatinine is not as accurate as inulin, as a slight amount is excreted, which 
can lead to overestimation of GFR. Nevertheless, its endogenous properties, 
as opposed to the exogenous inulin, make creatinine an easier, cheaper, and 
faster way to measure GFR in the clinic (42). 
 
1.2 THE PERITONEUM 
The peritoneal membrane (PM) is a smooth thin serous membrane 
surrounding the abdominal cavity and organs. The PM is anatomically 
divided into visceral and parietal peritoneum. The parietal peritoneum lines 
the abdominal cavity, whereas the visceral peritoneum surrounds the viscera. 
The PM can be compared to a plastic bag that is vacuum-sucked to the walls 
and organs around it in the abdominal cavity. A fluid film separates these two 
layers, serving as a lubricant (43). In an adult, the PM has a surface area of 1–
2 m2. The PM also serves as a mechanical anchor via the greater and lesser 
omentums that hold the stomach in place and mesenteries that anchor the 
intestines to the posterior abdominal wall. The mesenteries are double folds 
of the PM. The cavity surrounded by the PM is called the peritoneal cavity. 
This cavity consists of the lesser sack behind the stomach and the greater 
sack that extends from the diaphragm down to the pelvis (44). The blood 
supply of the visceral peritoneum comes from the mesenteric and the coeliac 
arteries, with the venous return going to the portal vein and then to the 
inferior vena cava. Different arteries supply the parietal peritoneum: the iliac, 
lumbar, intercostal, epigastric, and the circumflex arteries. Lymph drained 
from the PM is taken to the omental and mesenteric lymph nodes. The lymph 
is then taken to the thoracic duct, where it joins the venous circulation (14). 
Histologically, the PM consists of six layers: the capillary fluid film, the 
capillary endothelium, the endothelial basement membrane, the interstitium, 
the mesothelium, and the fluid film (45). The mesothelium consists of a 
continuous layer of single mesothelial cells connected by intracellular 
junctions (46). The cells are covered with microvilli, allowing for an 
increased surface area. These cells have lamellar bodies, endoplasmic 
reticuli, and cellular vesicles. The mesothelial cells participate in the PM 
barrier function. They can release vascular adhesion molecules and 
intracellular adhesion molecules in response to cytokines released by 
inflammatory cells (47). Underneath the mesothelium is a layer of collagen 
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and glycoproteins forming the basal lamina. The basal lamina offers 
mechanical support and allows for passage of inflammatory cells while 
preventing fibroblasts from penetrating to the mesothelial layer (48, 49). The 
interstitial layer of the PM is composed of collagen, elastin, proteoglycans, 
and a salty liquid. The components of this layer comprise the extracellular 
matrix of the PM. The interstitial layer, alongside the basal lamina, offers 
mechanical support to the mesothelium. The fibroblasts that are contained in 
this layer produce building components and are inflammatory active cells. 
This layer has macrophages and mast cells that, alongside fibroblasts, recruit 
leukocytes by the generation of chemokines and cytokines in case of 
inflammation. The PM plays an important role in keeping the peritoneal 
cavity aseptic. Other inflammatory active cells are the mast cells and the 
lymphocytes. An invasion of the integrity of the PM will lead to the 
activation of the macrophages, lymphocytes, mast cells, and fibroblasts. This 
activation then leads to the release of chemoattractants and the consequent 
recruitment of leukocytes to the inflammation site (50, 51). 
 
1.3 END-STAGE RENAL DISEASE 
End-stage renal disease (ESRD) is reached when the kidney function has 
decreased to a level where RRT is needed for survival. RRT may be either 
dialysis or renal transplantation.  ESRD is a leading cause of morbidity and 
mortality worldwide, and, as of 2010, number 18 on the list of global death 
rates (52). An estimated 2.3–7.1 million people with end-stage kidney disease 
died in 2010 without access to RRT (53). Furthermore, the incidence of 
ESRD has increased by 8% annually, due to an aging population as well as to 
the increased numbers of patients with type 2 diabetes and/or cardiovascular 
disease leading to renal impairment (54, 55).  
Renal transplantation is the first-hand choice of RRT in Sweden. Out of the 
9,693 patients in Sweden who are in uremic care, 5,641 have received a renal 
transplant (56). However, due to the lack of donors, it is not possible for all 
ESRD patients to undergo transplantation, leaving dialysis as the only RRT 
option. Dialysis is divided into hemodialysis (HD) and PD. In 2016, there 
were 3,039 Swedish patients on HD and 877 on PD (56). Recently, PD has 
increased in popularity over HD. One of the reasons for favoring PD is its 
flexibility of use at home or outside, offering a better quality of life (57). Due 
to its ease of use compared to HD, PD is also recommended in pediatrics 
(58). Furthermore, diabetes patients and patients with cardiovascular 
problems are generally advised to undergo PD as it offers better blood sugar 
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control and more controlled fluid and blood pressure changes than in HD (59-
62). Finally, PD is less expensive, making it advantageous for individual and 
population economic burdens (63, 64). Despite studies showing similar 
therapeutic outcomes between HD and PD, HD is still more commonly used 
for treating patients with ESRD (65). Taken together, this suggests that the 
choice of dialysis therapy is based on other facts than medical evidence. 
 
1.4 PERITONEAL DIALYSIS 
In 1896, peritoneal capillaries were used by Starling to define the 
fundamental principles governing fluid balance in all vascular beds (66). In 
1923, the peritoneum was discovered as a filtration barrier through the work 
of Ganter, who was the first to use dialysis in a uremic patient (67). In the 
same year, Putman described the PM as a dialyzing unit (68). However, it 
was not until the early '60s, that PD started being used worldwide as a 
treatment option for uremic patients (69). Continuous ambulatory PD 
(CAPD) was then developed in the late 1970s, by the work of Moncreif et al. 
(70). Their method introduced 1.5–3 l of a hyperosmolar peritoneal dialysis 
fluid (PDF) into the peritoneal cavity through a catheter in a process called a 
dwell. Five dwells a day were performed, seven days a week, which can be 
seen as a physiologic method for waste removal compared to HD.  
PD utilizes osmotic filtration that governs the blood solute and organic waste 
product movement from the blood into the peritoneal cavity. Dwell times 
range from four to eight hours, and after the diffusion of solutes is complete 
over the PM, the dialysate is drained out and new PDF is instilled (62). The 
injection and draining of PDF after a dwell are called a PD cycle. 
The success of PD as an RRT is dependent on the quality and preservation of 
the properties of the PM. The PM is different from one individual to the other 
in terms of the ability to remove solutes and waste products. Variations in 
microvasculature and mesothelial and interstitial properties between 
individuals can lead to different therapeutic outcomes (71). PD has shown 
good outcomes in terms of survival. However, after seven years of PD, only 
10% of the treated patients can remain on PD due to ultrafiltration failure 
(UFF) and peritonitis of the PM (72-74). 
UFF is defined as having a net UF that is less than 400 ml at four hours of 
dwell using a hypertonic PDF in the absence of PDF leaks, catheter 
malfunction, or adhesion blockage (75-77). UFF has four types: high 
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effective peritoneal surface area (type 1), characterized by hyperpermeable 
PM to small solutes; low osmotic conductance to glucose (type 2), due to 
aquaporin dysfunction; low effective peritoneal surface area (type 3) with 
decreased solute and water transport (rare); and high total peritoneal fluid 
loss rate (type 4) with increased reabsorption of dialysate due to increased 
lymphatic flow (78). 
Type 1 is the most common type to cause permanent UFF. It develops over 
time and features vascular damage and endothelial dysfunction. As a result, 
more protein is lost and more glucose reabsorbed from the PDF. The 
pathogenesis of this UFF is speculated to be due to uremia and the chronic 
exposure to high glucose PDF (79).  
Since the abdominal cavity is penetrated in PD, there is an increased risk for 
infection and peritonitis. Infection can occur via the transluminal or 
periluminal ways. Transluminal infections may occur during PD cycles, 
while periluminal infections may occur due to a permanently implanted 
catheter (80, 81). The causative pathogens can be gram-positive or gram-
negative microorganisms. Gram-positive cocci such as Staphylococcus 
epidermidis, other coagulase-negative staphylococci, and Staphylococcus 
aureus are responsible for up to 40% of all cases of infectious peritonitis 
worldwide (82, 83). Various other microorganisms can also penetrate to the 
peritoneal cavity (84). 
Peritonitis is the major source of morbidity and the transfer of dialysis 
regimen to HD (85, 86). A cascade of inflammatory processes marks 
peritonitis. The interaction of macrophages, lymphocytes, fibroblasts, and 
mast cells in the PM with the invading organisms will lead to accumulation 
of various inflammatory mediators and growth factors such as transforming 
growth factor beta (TGF-β) and vascular endothelial growth factor (VEGF). 
The result of this inflammatory state is a paradoxically disadvantageous 
increment in the effective PM surface area due to angiogenesis and 
subsequent hyperpermeability (type 1 UFF). The other results are fibrotic 
events with thickening of the PM and further UFF (77, 87, 88). 
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1.5 RENAL CARCINOMA 
Renal cancer is the ninth most common cancer form in men and the 
fourteenth most common cancer in women. In 2018, it is estimated that 
403,262 new cases of kidney cancer will be reported, of which 175,098 
deaths will occur (89). According to the 2016 World Health Organization’s 
(WHO) classification of tumors of the urinary system (90), RCCs are the 
most common types of renal cancers and are usually unilateral. RCCs are 
subdivided into several types (see Table 1). The most common types are 
ccRCC, papillary renal cell carcinoma, chromophobe renal cell carcinoma, 
acquired cystic (solid) disease-associated renal cell carcinoma, collecting 
duct carcinoma, renal medullary carcinoma, and unclassified RCC. Together, 
these subtypes account for approximately 90% of all RCCs. ccRCC alone 
accounts for approximately 70% of all RCCs (90, 91) and originates from 
PCT cells (6, 92). With a ratio of 1.5:1 for men and women, it is most 
commonly diagnosed around the age of 40, nevertheless, any age group can 
develop ccRCC. The strongest non-genetic risk factors are smoking and 
obesity, albeit it develops sporadically in most cases (6). A triad of symptoms 
can present ccRCC, namely hematuria, flank pain, and a palpable mass. 
However, only 10% of patients present these symptoms, 40% do not show 
any of these symptoms, and the rest show different combinations of these and 
other symptoms. ccrCC is genetically characterized by mutation in genes that 
control cellular oxygen sensing (such as Von Hippel–Lindau (VHL)) and the 
maintenance of chromatin states (such as PBMR1). The inactivation of the 
VHL gene leads to a defect in the ability to degrade hypoxia-inducing 
transcription factors HIF-1α and HIF-2α, which in turn leads to increased 
transcription of hypoxia-inducing genes like VEGF and glucose transporter 
1 (GLUT1) (93, 94). ccRCC holds the most sarcomatoid transformation 
potential and is the most aggressive of all RCC types (95). The lack of 
surveillance methods, sporadic occurrence, and vague symptoms in more 
than 50% of the ccRCC patients lead to late detection of this cancer form, 
with accidental detection in up to 60% of cases (96). Localized ccRCC can be 
treated with surgical removal (97). Metastasized ccRCC, however, is highly 
resistant to chemo- and radiotherapy (98, 99). Some of the treatment options 
for ccRCC include immunoregulatory drugs (100), VEGF receptor and 
multityrosine kinases inhibitors (101), and the mammalian target of 
rapamycin (102). Therapy can impede the progression of the metastases in 
ccRCC for approximately three to six months. However, for the overall 
survival, few clinical trials have offered a statistically meaningful effect (103-
105). Taken together, these factors lead to ccRCC being detected at a late 
stage, with the highest mortality rate of the genitourinary cancers of up to 
40% (106).  
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The ccRCC cells are divided into primary and metastasized cells. The most 
common metastatic locations for ccRCC are the lungs and bones, followed by 
the liver, lymph nodes, brain, breasts, and adrenal glands (107). Establishing 
RCC cell lines is important for exploring the mechanism of renal 
carcinogenesis and for developing therapeutic options. E. Oosterwijk created 
a library of RCC cells acquired from the Sloan-Kettering (SK) Memorial 
Cancer Center. These renal cancer cells were named SKRC cells. Forty-six of 
these SKRC cells were derived from primary kidney tumors and 17 were 
derived from metastatic sites (lung, brain, bone, and lymph node) (108). 
 
Renal Cell Tumors 
Clear cell RCC 
Multilocular cystic renal neoplasm of low malignant potential  
Papillary RCC 
Hereditary leiomyomatosis and RCC associated RCC 
Chromophobe RCC 
Collecting duct carcinoma  
Renal medullary carcinoma  
MiT family translocation RCCs  
Succinate dehydrogenase-deficient RCC 
Mucinous tubular and spindle cell carcinoma  
Tubulocystic RCC 
Acquired cystic disease-associated RCC 
Clear cell papillary RCC 
RCC, unclassified  
Papillary adenoma Oncocytoma  
Table 1. Renal cell carcinoma subtypes by the WHO, 2016 (90). MiT, microphthalmia 
transcription factor; RCC, renal cell carcinoma. 
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1.6 ORELLANINE 
Orellanine is a nephrotoxin found in mushrooms of the Cortinariaceae 
family, which includes the fool’s webcap (Cortinarius orellanus) and the 
deadly webcap (Cortinarius rubellus) mushrooms. These mushrooms grow in 
the forests of Northern Europe and North America. Orellanine was 
discovered after the epidemic of mushroom poisoning in Poland in 1952 and 
has since been examined for its toxicity (109). The chemical form of 
orellanine is [2, 2′-bipyridine]-3, 3′,4, 4′-tetrol-1, 1′-dioxide (110). It is 
present in the mushroom as a di-glycoside (111, 112). Once digested, 
orellanine containing mushrooms can cause symptoms like flank pain, 
polyuria followed by oliguria, and dehydration. These symptoms are 
concordant with nephrotoxicity and their emergence varies in time. 
Symptoms may appear as early as the second day but the majority of patients 
develop these symptoms between one and up to two weeks after ingestion. 
Since there are no known antidotes for orellanine poisoning (113), treatment 
options that have been tested are hemodialysis, plasmapheresis, and 
acetylcysteine (114). The outcomes after ingestion can vary from complete 
remission to total kidney failure (uremia). There seems to be a dose 
dependency in the severity of renal impairment. Histologically, kidney 
lesions include tubulointerstitial nephritis with severe interstitial fibrosis, 
interstitial edema, and tubular epithelial necrosis (115, 116). The uremia is 
characterized by high blood levels of urea and creatinine (117). Once uremic, 
the patients will be dialysis-dependent for life. If the uremia is managed with 
dialysis or kidney transplantation, the patients will live a normal life as no 
other organs than the kidneys seem to be affected by orellanine (5). 
Orellanine’s median lethal dose (LD50) in a mouse is approximately 20 mg/kg 
(118). The LD50 in humans is not known but is estimated to be much lower 
(4). Orellanine seems to be taken up selectively by PCT cells and there 
generally are no detectable amounts of the toxin in the plasma or urine by the 
time the symptoms emerge (3, 119). Kidney tissue can have detectable 
amounts of orellanine up to 6 months after poisoning, suggesting 
accumulation in the PCT, but this has not been validated (120). 
The molecular weight of orellanine is 252.19 g/mol and it has four pKa 
values of approximately 0.5, 1.0, 7.0, and 7.4. The net charge at physiological 
pH is close to -4. The pure form of orellanine is a colorless fine crystalline 
substance that, if exposed to ultraviolet light, will decompose to orellinine 
and subsequently to the nontoxic orelline (3).  
The exact mechanism of action of orellanine is unclear. What is known so far 
is that orellanine induces cell damage by a rapid change from its oxidized to 
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its reduced form, leading to the induction of oxidative stress (4, 121). 
Simultaneously, orellanine shuts down the enzymatic oxidative defense 
features of the orellanine sensitive cells (4). The subsequently induced 
hypoxia renders the cells susceptible to oxidative destruction. Orellanine 
works mainly at the nephron tubular brush border with a variety of actions 
such as the inhibition of synthesis of proteins, DNA, and RNA (122), the 
inhibition of enzymatic activity like alkaline phosphatase and leucine 
aminophosphatase, and the interruption of adenosine triphosphate (ATP) 
production (123). Due to the oxidative stress induction features of orellanine, 
antioxidant therapy has shown some improvement in minor intoxications 
(124, 125). 
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2 AIMS 
The general aim of this doctoral thesis is to explore the effectiveness, 
pharmacokinetics, and potential uses of the fungal nephrotoxin orellanine in 
PD research and as a potential treatment against metastasized ccRCC. 
The specific aims of the papers included in this thesis were as follows: 
Paper I: The first aim of paper I was to investigate whether orellanine can be 
used to induce chemical nephrectomy instead of nephrectomy induced by 
surgery. The second aim was to develop a new method for chronic automated 
PD (APD) in anuric rats.  
Paper II: The aim of paper II was to explore the distribution and 
pharmacokinetics of orellanine in rats to understand how orellanine is cleared 
from the body.  
Paper III: The first aim of paper III was to investigate orellanine’s selective 
nephrotoxic effects on proximal tubular cells. The second aim was to explore 
if this toxicity extends to primary and metastasized ccRCC cells both in vitro 
and in vivo for orellanine to be considered as a future treatment option against 
ccRCC.  
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3 METHODOLOGICAL CONSIDERATIONS 
 
3.1 SUMMARY OF METHODS 
Paper I: The first paper in this thesis was a methodological PD study that 
tested a novel APD system developed by our group on female Wistar rats. 
Orellanine was used to induce chemical nephrectomy in order to test the 
system on anuric rats. Inflammatory changes on the peritoneum and the 
electrolytes’ profiles in blood and dialysate were examined.  
Paper II: The second paper investigated the pharmacokinetics of orellanine in 
male Sprague Dawley rats. The rats received orellanine (labeled or unlabeled) 
intravenously (iv) and plasma samples were collected over eight subsequent 
time points. Ultra performance liquid chromatography-tandem mass 
spectrometry (UPLC-MS/MS) and beta scintillation were used to measure the 
halftime and clearance of orellanine in plasma. Additionally, anuric and 
healthy rats received labeled orellanine iv and were then sacrificed at 
different time points. Radioilluminography was then used to visualize the 
distribution of orellanine in the body. 
Paper III: The third paper comprised an in vitro and in vivo part. In the in 
vitro part, human kidney tubular cells, non-kidney cells, and anaplastic cell 
lines were tested in terms of response to orellanine. In the in vivo part, human 
ccRCC was xenografted into immunodeficient Sprague Dawley rats. The 
animals were then put on dialysis and half of the animals received orellanine 
treatment intraperitoneally (ip). Excision of tumor masses occurred on the 
day of autopsy and comparisons were done on morphological, histological, 
and cellular levels. 
 
3.2 ANIMALS 
All the in vivo experiments in this thesis used PD as a RRT. Choosing the 
right animal species and strain is one of the challenges in PD research (126). 
The most commonly used animals in PD models are mice, rats, and rabbits 
(127). Although mice are inexpensive and easy to breed, their miniature size 
makes them hard to perform surgery on (128). Rabbits are able to undergo 
PD, with the advantage of having a PM surface area similar to humans. 
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However, these animals are very sensitive, expensive, and difficult to breed 
(129). Rats are the most commonly used animals in PD research. Rats are 
also affordable and easy to handle (130, 131). The disadvantages of using rats 
include a larger PM surface area compared to humans (132, 133) and higher 
amounts of amylase enzyme in the peritoneal cavity (134, 135). 
All experiments in this thesis were performed on rats. Male and female 
Sprague Dawley and female Wistar rats were used. From our own 
experience, female Wistar rats formed the least adhesions in the peritoneal 
cavity around the implanted catheters and were therefore used for the chronic 
PD model. All animals were kept in a temperature-controlled environment on 
12-hour light cycles and were fed a standard rodent chow and water ad 
libitum. 
 
3.3 PAPER I METHODS 
3.3.1 Chemical nephrectomy 
In clinical settings, a patient in need of RRT will be uremic (136-138). 
Therefore, it is important that animal models of PD reflect this by using 
uremic animals. Besides, uremia itself might induce independent effects on 
the PM other than those from PD alone (139, 140), which adds to the need 
for a uremic PD animal model. There is currently a lack of totally uremic 
animal models of chronic PD (131). This is partly due to challenges in 
finding a method for inducing total uremia that is reproducible and mimics 
the clinical setup. Uremia in animal models is typically induced by subtotal 
(5/6) nephrectomy (141). This can be performed by uni-nephrectomy and 
subsequent ligation of two of the three branches of the renal artery on the 
remaining kidney (142, 143), or by the ablation method, in which uni-
nephrectomy is performed and 50% (or more) of the remaining kidney is 
surgically removed. Pertaining to the utilization on rats, the ligation model 
poses a severe hypertension threat to the rat’s circulation (144, 145), whereas 
the ablation model is hard to reproduce, causes varying grades of renal 
failure, and is dependent on the performer of the surgery (146). In addition, 
both procedures include major surgical trauma and pose an increased risk for 
infection, making them unreliable methods for chronic PD(147). Therefore, 
our model used orellanine in order to achieve total chemical nephrectomy. 
Orellanine specifically causes renal failure both in humans and animals (112, 
114, 120). Using orellanine is non-invasive and minimizes the risk for 
dropouts due to surgery. To ensure anuria occurrence, three extra groups of 
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rats (three animals in each) were injected with an ip bolus dose of 5, 7, and 
10 mg/kg orellanine without PD. Blood samples were collected at day 3 after 
the injection. Uremia was evident in all three groups with high serum urea 
and creatinine levels (see Figure 2). Therefore, the lowest dose was chosen 
for the chemical nephrectomy (5 mg/kg). 
 
Figure 2: Serum creatinine (A) and urea (B) levels two days after three different single ip 
doses of orellanine. 
 
3.3.2 PD of rats 
 
3.3.2.1 Chronic PD 
Patients on dialysis will need lifelong RRT, unless a successful 
transplantation occurs. Animal models aiming to improve PD treatment 
should, therefore, be performed chronically and on uremic animals (131). 
One day in an adult rat corresponds to 34.8 days in a human’s lifetime (148). 
Hence, our 21 days of PD treatment in rats could be compared to 2 years in 
humans. 
3.3.2.2 Peritoneal access 
The literature describes three major ways to perform PD dwells (126). One 
method is by simply injecting the PDF into the peritoneal cavity and letting 
the PDF be absorbed. This method implies repeated injections with the 
accompanying risk of infection and trauma to internal organs. In addition, 
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repeated anesthesia can alter the PM permeability and kinetics (149, 150). 
The second method is via a temporary catheter with manual draining or 
leaving PDF in for absorption. The third method uses an implanted catheter 
with repeated dwells and emptied manually or by gravitational force. The 
latter method does not cause repeated trauma or anesthesia. However, the risk 
of peritonitis is increased with repeated handling of the implanted catheter 
(126). Our PD setup used the third method but instead of manual handling of 
the catheter, we used a computerized automated dwell and emptying valve 
system in order to further minimize the contamination risk. 
3.3.2.3 Novel APD rat model 
The PD model developed in our lab uses a catheter (CBAS-50, Instech 
Laboratories Inc., PA, USA) that is surgically implanted in the peritoneal 
cavity. The catheter is passed subcutaneously to the back of the rats’ neck 
and fitted to a harness (SAI Infusion Technologies, USA). The harness has 
sealed valves that fit a swivel (custom-made in our lab) connected to the PD 
tubing system. The PDF used is Gambrosol® trio 10 containing 1.5% 
glucose. The model operates using hydrostatic pressure for filling and 
emptying each dwell. The tubing system is sealed and sheathed by a water 
bath to keep the fluids inside the tubes at body temperature before they enter 
the peritoneal cavity of the rats. All tubing and housing units are autoclaved 
before each experiment. The APD system allows for automatic dwells and 
emptying of the peritoneal cavity of the rats while being completely 
controlled from a computer program. The latest version of the APD system 
provides five standardized and timely regulated dwells a day. The computer 
software administers customized filling, dwell, emptying times, and numbers 
of cycles. In order to ensure that the system was running without any 
problems during the dwell time, monitoring was carried out daily. The rats 
were housed in separate cages, which were placed in a Scantainer (Scanbur 
Technology A/S, Denmark), providing optimized humidity, light and dark 
cycles, and air-flow and keeping a sanitary environment for the rats during 
the dialysis period (Figure 3). In order to evaluate the effectiveness and 
function of the dialysis, dialysate fluid was collected from the second cycle 
on the first day and the last day of the three weeks of the APD period. Blood 
and tissue samples were taken on the day of autopsy after finishing the 
dialysis period. 
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Figure 3. The Scantainer at the experimental biomedicine core facility (EBM). The rats are 
kept in separate cages. Cameras monitor the rats while the doors are closed. Humidity, sterile 
air-flow, temperature, and light cycles are standardized by the container functions. 
 
3.3.2.4 Peritonitis 
Infection and subsequent peritonitis pose the greatest threats to the integrity 
of the PM and its ability to yield effective PD chronically. Therefore, several 
precautions were taken to avoid contamination. The laboratory environment 
was aseptic. Animals were housed in a Scantainer that provided controlled 
temperature, relative humidity, air changes per hour, and positive or negative 
pressure under sterile conditions. All equipment entering the laboratory was 
autoclaved. Animals were washed twice with chlorhexidine before surgery. 
Before surgery and implantation of the PD catheter, the animals were covered 
in sterile plastic sheeting. The surgeon prepared the same way as to perform 
clinical surgery, wearing sterile clothing, mask, mouth protection, and sterile 
gloves. All PD tubing was autoclaved and connected aseptically to each 
animal and the sterile PD fluid. Each catheter was coated with heparin, as this 
method yielded efficient results by means of avoiding adhesions, fibrosis, and 
subsequent dropouts (151). Prophylactic antibiotics were used in the PD fluid 
to prevent peritonitis from the rats’ own intestinal bacteria as well as external 
infection, thereby decreasing dropout rates evident in our own experience as 
well as in literature (152, 153).   
In order to monitor the inflammatory profile of the PM, the following growth 
factors and interleukins were measured: VEGF, transforming growth factor 
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beta (TGF-β), interleukin-1beta (IL-1β), and interleukin-6 (IL-6). VEGF is a 
glycoprotein that is activated in response to hypoxia (154) and exposure to 
high glucose PDF (155, 156). The result is the induction of neoangiogenesis 
and subsequent hyperpermeability of the PM (type 1 UFF) (157). TGF-β 
accumulation across the PM extracellular matrix leads to increased fibrosis 
and epithelial to mesenchymal transition (EMT) (158, 159). VEGF and TGF-
β are suggested to interplay, leading to a synergized negative effect on the 
outcomes of PD, which makes these cytokines significant to measure in PD 
testing (160). Interleukin-1β and 6 are pro-inflammatory cytokines used as 
predictors of peritonitis, as they are produced by inflammation-mediating 
cells like dendritic cells, NK cells, T cells, B cells, monocytes/macrophages, 
fibroblasts, mesothelial cells, and vascular endothelial cells (161, 162). 
3.3.2.5 Solute profiles 
The electrolytes and molecules examined to test the PD quality were urea, 
creatinine, sodium, potassium, phosphate, calcium, glucose, and albumin. 
Creatinine is the breakdown product of muscle creatinine phosphate. The 
kidneys remove creatinine constantly through the glomerulus and the kidney 
tubules. The amount of creatinine can therefore be measured in the blood to 
evaluate kidney and PD function in chronic kidney disease (CKD) and ESRD 
patients. Urea is produced by the liver and is the major end product of 
breakdown of amino acids. Serum urea level is utilized as an indicator of the 
extent of renal failure (163). 
ECF volume expansion due to disturbances in sodium levels is a common 
problem in CKD and ESRD patients. This leads to salt-sensitive hypertension 
and subsequent left ventricular hypertrophy (164). Diuretic treatments have 
not proven to be effective (165), making sodium a central electrolyte to 
monitor in PD to make sure that excess is excreted through the PM. 
Potassium is an important intracellular electrolyte needed to maintain 
membrane potential over the cardiac muscle; a slight change in potassium 
balance may lead to arrhythmia and cardiac arrest. The kidneys play an 
important role in potassium balance by excreting up to 98% of the daily 
excess intake of potassium. Renal failure will lead to impaired potassium 
excretion and hyperkalemia, which is the most important and fatal 
complication of renal failure (166, 167). Other measured electrolytes are 
phosphate and calcium. These electrolytes are involved in bone mineral 
metabolism. Their homeostasis is orchestrated by an interplay between the 
kidneys, parathyroid hormone, the gastrointestinal canal, and the bone tissue. 
The kidneys excrete both calcium and phosphate. In addition, ESRD can lead 
to abnormalities in bone turnover and soft tissue calcification (168). Several 
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factors play a role in altering the glycemic homeostasis, making glucose a 
central electrolyte to monitor especially in patients with diabetes. These 
factors include uremic toxin accumulation, hepatic and renal impaired insulin 
degradation, malnutrition, low vitamin D production, secondary 
hyperparathyroidism, and PDF glucose load. These factors indicate the 
importance of close measurements of glucose profiles in patients with kidney 
failure on PD (169). Albumin, phosphate, and glucose can be indicators of 
the nutritional status of patients with ESRD on PD. ECF volume expansion, 
exogenous loss due to PD, and decreased albumin synthesis all contribute to 
hypoalbuminemia, making albumin a standard protein to test the quality of 
PD and the nutritional status of the patients (170).  
In summary, our dialysis method is unique in three ways: first, it uses a 
chemical nephrectomy to induce uremia. Second, this is the first study to 
apply APD on rats in a fully computerized manner. Third, our dialysis 
method is also the first to study the changes of the PM over a chronic period 
of time in anuric rats while keeping normal homeostasis throughout the 
experiment time. 
 
3.4 PAPER II METHODS 
 
3.4.1 Radioiluminography 
In laboratory animals, whole-body radioiluminography is used to determine 
the distribution and concentrations of radiolabeled drugs and compounds. 
This technique provides information on tissue penetration, accumulation, and 
retention. Briefly, animals receive a radiolabeled dose of a certain compound. 
At specific time points, after the administration of the dose, the animals are 
euthanized under anesthesia and the whole body is frozen in a 
carboxymethylcellulose matrix. The frozen carcasses are then cryosectioned 
and cross-sectional whole-body sections from different depths are obtained. 
The representative sections with the tissues of interest are then exposed to a 
phosphor-imaging scanner that produces high-quality images emphasizing 
the radiolabeled areas in tissues and body fluids (171, 172). The rats used for 
this experiment were male Sprague Dawley rats (Taconic, DK).  
Orellanine was labeled using tritium (3H). The radiolabeling of orellanine 
was performed by the Red Glead Discovery AB (Lund, Sweden), resulting in 
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> 95% bound 3H-labeled orellanine with a specific activity of 35.5 Ci per 
mmol orellanine. Ten rats received a single dose of 5 mg/kg of 3H-labeled 
orellanine iv (vena saphena). Twelve rats received a nephrotoxic dose (5 
mg/kg) of unlabeled orellanine ip 72 hours prior to the introduction of 5 
mg/kg of the 3H-labeled orellanine. The reason for rendering the second 
group of rats anuric is to determine how the distribution of orellanine will be 
affected without kidney clearance. 3H-labeled orellanine was prepared with a 
formula of 0.471 mCi/mL, corresponding to 1.25 mg/mL in physiological 
saline, while unlabeled orellanine was formulated to 1.25 mg/mL in 
physiological saline. The administered volume was adjusted to 4 ml/kg for 
each rat after weighing. Under isoflurane anesthesia, blood samples were 
collected from the tail veins at time points 0.5, 1, 6, 12 (last point for the 
nephrectomized rats group), and 24 hours after administration of orellanine. 
The rats were then sacrificed. The carcasses of the anesthetized animals were 
immersed in heptane cooled to -70°C. Each carcass was embedded in 
carboxymethyl cellulose and 30 µm thick sagittal sections were taken at 
different depths. The sections had radioactive labels and were placed on 
imaging plates (Fuji, Japan). Light-tight cassettes were used for exposure and 
had lead shielding at -20°C in order to cancel out environmental radiation.  
3H-radioactivity calibration standards were used in this method consisting of 
10 dilutions from 6.68–22400 nCi/g for the single dose experiments and 
6.60–11260 nCi/g for the nephrectomized rats experiments. All tissues were 
assumed to have a similar density (1 g/mL) and quench characteristics as 
whole blood. The mean concentration value of eight measurements for 
background plus triple the standard deviation values for the same 
measurements were used to define the limit of quantification. 
The 30 µm sections and the calibration standards were put on imaging plates 
and exposed for 70–96 hours, then scanned with a 50 µm pixel size using 
BAS 2500 (Fuji Film, Sverige Ab, Sweden). Quantification was done using 
AIDA software, version 4.19 (Raytest, Germany). The mean value of three 
separate sections for each tissue was used to determine the radioactivity. 
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3.4.2 Detection of orellanine in plasma 
Since orellanine is investigated for its quality as a chemical nephrectomy tool 
in a PD animal model and for its possible therapeutic effects in treating 
metastasized ccRCC, it is important to develop a method to detect orellanine 
levels in plasma. This is done in order to control the therapeutic steady-state 
window and to investigate the half-life. Another important clinical aspect is 
the need to have a reliable method for detecting orellanine in fluids and 
plasma of suspected cases of orellanine intoxication.  
Efforts have been taken to detect orellanine levels in mushrooms, plasma, and 
kidney tissue before. Orellanine was discovered in mushrooms using thin 
layer chromatography (TLC), electrophoresis, electron spin resonance (ESR), 
and reversed high performance liquid chromatography (HPLC) (173, 174). 
HPLC with an electrochemical detector has also been used to detect 
orellanine in serum and kidney tissue (174, 175). Orellanine has been 
detected in single MS mode using electron impact (EIMS) and electrospray 
ionization (ESIMS), however; HPLC-ESI-MS/MS was only employed for 
qualitative purposes (111, 175, 176). Herrmann et al. optimized a quantitative 
HPLC-ESI-MS/MS liquid method for detecting orellanine in orellanine-
spiked blood plasma (16). One of the limitations was, however, that no 
plasma analysis was performed in vivo on animals dosed with orellanine. In 
our study, we used a modification of the latter method using UPLC-MS/MS 
(112).  UPLC-MS/MS combines the physical separation features of liquid 
chromatography with the mass analysis features of mass spectrometry, 
having high sensitivity and selectivity in detecting complex compounds. 
Since this experiment was done within a single day, there was no need to use 
female Wistar rats in order to avoid the formation of intraperitoneal 
adhesions in rats undergoing PD. Three groups of rats received an iv dose of 
orellanine (5 mg/kg) into the jugular vein. One group had intact kidneys and 
urine production, the second group had ligated kidney arteries, and the third 
group had ligated renal arteries and underwent PD. In this manner, the effect 
of PD on the elimination of orellanine could be examined. Blood was 
collected at seven subsequent time points: 10, 30, 45, 60, 90, 180, and 360 
min. The whole experiment was conducted under isoflurane anesthesia and 
the rats’ body temperature was kept at 37 °C with a heating pad. UPLC-
MS/MS was used to measure orellanine and beta scintillation was used to 
detect 3H-labeled orellanine and any metabolites formed.  
For the UPLC-MS/MS, a standard curve was diluted from a stock solution of 
200 µg/mL orellanine with human plasma to final concentrations of 0.039, 
0.78, 0.16, 0.31, 0.63, 1.25, 2.5, 5, 10 and 15 µg/mL. 
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The quality control samples were prepared from the same stock solution and 
diluted with human plasma to final concentrations of 1.25 and 5 µg/mL. 
Human plasma was used instead of rat plasma for quality control sample 
preparation to enable a better comparison between the UPLC-MS/MS runs 
and to eliminate variations due to experimental conditions. The quality 
control samples were analyzed before and after each tested unknown plasma 
sample. As a result, large amounts of plasma were needed for the quality 
control samples. We opted to use human plasma as it is easier to obtain in 
larger volumes than animal plasma. Furthermore, in experiments performed 
earlier in our lab, the plasma protein binding of orellanine after 4 hours of 
dialysis was found to be quite low, 33.5% for rats and 42.5% for humans. 
The small difference makes it unnecessary to sacrifice more animals and use 
rat plasma. 
Small molecules were separated from proteins when the samples were 
filtered with a 30 kDa molecular weight cut-off filter. The filters were 
transferred to high recovery tubes and 64 µL of 5.2% formic acid (v/v) was 
added to the filters. 20 µl of the rat plasma samples or the quality control 
samples were added to the filter for a final concentration of 4% formic acid 
(v/v). The samples were centrifuged for 30 min at 1200 rpm and then injected 
(volume 7.5 µL) into a Zorbax Eclipse plus C18 columns, with the 
dimensions 150 x 2.1 mm, 5 µm particle size (Waters, Milford, MA, USA). 
Separation temperature was at 45°C, with a flow rate of 200 µL/min. 
Orellanine with parent mass m/z 253.05 Da was fragmented, where fragment 
ion mass per charge (m/z) of 236.2 Da indicated the loss of 17 Da, 
corresponding to a loss of OH, which was extracted for quantification. The 
quality control samples were within 10% difference compared to the standard 
curve. The lowest detected concentration was 40 ng/ml. Orellanine was 
extracted in plasma with 60% efficiency. All samples were analyzed with 
parallel reaction monitoring on an LTQ Orbitrap Velos mass spectrometer 
interfaced to an UltiMate 3000 system (Thermo Fisher Scientific, Waltham, 
MA, USA). The results were analyzed with Xcalibur software (Thermo 
Fisher Scientific, Waltham, MA, USA). The average peak from two 
injections of each sample was then calculated. The quality control samples 
were analyzed before and after each tested unknown plasma sample. This 
allowed for a better comparison between the UPLC-MS/MS runs and to 
eliminate variations due to experimental conditions. In the chromatogram 
analysis of the quality control samples, orellanine had a retention time (RT) 
of 5.2 min (see Figure 4). 
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Figure 4: Chromatogram from quality control sample with a plasma concentration 
corresponding to 1.25 and 5 µg/mL. 
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3.5 PAPER III METHODS 
 
3.5.1 In vitro studies 
Before testing orellanine in an in vivo rat xerograph tumor model, the effects 
were examined in vitro on proximal tubular cells and ccRCC primary and 
metastasized cell lines. HTEC were prepared from tissue taken from the 
cortical region of the healthy part of a nephrectomy kidney. All specimens 
were collected after informed consent from the patient. Proximal tubular cells 
are the origin cells for ccRCC (6, 92). The effect of orellanine was examined 
on HTEC cells in comparison to other cell lines. The non-renal cell line 
chosen was human umbilical vein endothelial cell line (HUVEC) (Lonza 
LTD, Basel, Switzerland). The malignant non-renal cell lines chosen were 
from a metastatic region of an epithelial cell breast adenocarcinoma cell line 
MDA-MB-231 (ATCC® HTB-26™) and human liver carcinoma cells 
(HPEG2). Renal cancer cell lines were either primary ccRCC tumor cells or 
metastatic ccRCC cell lines. Primary cell lines were 786-O cells 
(ATCC® HTB-26™), 087, or SKRC-7, -10, and -21. The metastatic cell lines 
were SKRC-17 and -52. The SKRC cells were obtained from the work of E. 
Oosterwijk (Radboud University Nijmegen Medical Center, Nijmegen, The 
Netherlands) (108). SKRC-17 and -52 are associated with poor prognosis and 
strong resistance to treatment. We utilized these cells in order to test our 
methods on the cells most difficult to treat. 
3.5.1.1 Apoptosis 
Apoptosis is the sum of cellular changes leading to programmed cell death, 
such as cell shrinkage, DNA fragmentation, and cell membrane changes. 
Apoptosis is part of the normal cell life cycle but can be induced in response 
to toxins and cell damage (177). The signaling pathways for apoptosis are the 
intrinsic and the extrinsic pathway. The intrinsic pathway is activated within 
the cell while the extrinsic pathway is activated from outside the cell (177). 
Caspases are proteins with protease activity that either initiate (caspase-8, -9) 
or execute (caspase-1, -6, -7) the signaling pathways, leading to apoptosis 
(178). Caspase-3, -8, and -9 enzymes were quantified in orellanine-treated 
cells in vitro, using western blotting and caspase activity assays. 
Annexin V binds to the phosphatidylserine (PS) lipids of the cells plasma 
membrane. In apoptosis, PS is exposed to the outer layer of the plasma 
membrane (otherwise restricted to the inner layer) and annexin V can bind to 
it. Annexin V can therefore be used to detect apoptosis. During necrosis, the 
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cell membrane is broken and annexin V can bind to PS and serve as an 
indicator of necrosis. Propidium iodide (PI) is used as a co-stain to annexin 
V, as it only enters necrotic cells and thereby indicates necrosis (179). This 
staining was used on cultured cells treated with orellanine to measure the 
apoptotic and necrotic profiles of the treated cells. 
3.5.1.2 Reactive oxygen species 
Some of the major reactive oxygen species (ROS) in living systems are 
superoxide, hydrogen peroxide, singlet oxygen, and hydroxyl radicals. 
Oxidative species are produced by cells in physiological situations during 
cellular metabolism. ROS are involved in anti-inflammatory functions, cell 
signaling, and proliferation. Uncontrolled ROS activation can cause cellular 
damage by mediating the oxidation of lipids, protein, and DNA (180, 181). 
ROS detection tests were performed using carboxy-H2DCFDA (6-carboxy-
2',7'-dichlorodihydrofluorescein diacetate). Carboxy-H2DCFDA is a 
chemically reduced, acetylated form of fluorescein used as an indicator for 
ROS in cells. The ROS species detected are singlet oxygen, hydroxyl 
radicals, and/or superoxide (182). Since orellanine has been shown to 
increase oxidative stress and induction of free radical formation (see section 
on orellanine), ROS detection was used to examine orellanine’s effect on 
cells in vitro. 
3.5.1.3 Cellular energy metabolism 
Cells generate energy in the form of ATP by oxidative phosphorylation 
and/or glycolysis (183). Oxidative phosphorylation is an aerobic pathway 
(requiring oxygen) that occurs in the mitochondria. Glycolysis is an 
anaerobic pathway that occurs in the cytoplasm outside the mitochondria 
(184). The oxygen consumption rate reflects oxidative phosphorylation, and 
the extracellular acidification rate reflects the glycolytic energy generation 
(185). These can be monitored by using a Seahorse XFp extracellular flux 
analyzer (Seahorse Biosciences, North Billerica, MA) on cultured cells to 
detect orellanine’s oxidative stress induction and the shift of treated cells to 
the anaerobic pathways. 
 
3.5.2 Xenograft animal model 
Wistar-Lewis rats were considered as tumor models since the 
adenocarcinomas in these rats can develop into ccRCC tumors with 
metastatic potential. This tumor model shares characteristics with the human 
ccRCC but is not exactly the same in terms of cholesterol metabolism and 
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growth. In Wistar-Lewis rats, the tumor size doubling time is 2 days 
compared to 240–600 days in humans (186). Other difficulties with this 
model were the unpredictable metastatic or growth patterns and the 
complexity in implantation (187, 188). Since the Wistar-Lewis model was 
not optimal for our purpose of testing orellanine on metastasized ccRCC, it 
was decided to use a xenograft rat model. 
Initially, a xenograft tumor model in immunocompromised rats was used. 
Athymic Sprague Dawley rats lacking T-cell function were chosen. We 
decided to implant the xenograft of ccRCC cells subcutaneously in order to 
be able to continuously measure the size of the tumor in the treated and 
control rats. 
Surprisingly, the immune system in rats with functional B cells defense led to 
reabsorption of the tumor within one to two weeks. This led us to induce 
further suppression of the immune system of the athymic rats with a 4–5 
Gray whole-body radiation dose, two weeks before the start of the 
experiment. This, in turn, initiated the successful growth of the injected 
ccRCC cell mass into a growing tumor within two weeks. The general 
growth and the appetite of the animals were not affected by this dose. The 
ccRCC cells implanted in the animals were SKRC-17. These cells were 
chosen as they are metastatic cells and they have higher resistance to 
treatment than the other cell lines tested. Orellanine was given ip with the 
PDF. During orellanine treatment, the rats underwent APD with the same 
setup used in paper I. At the end of the experiment time, the tumors were 
compared in terms of volume, weight, and assessment of in situ cell death 
with terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
assay. TUNEL assays can measure single- and double-stranded DNA 
fragmentation. Terminal deoxynucleotidyl transferase assists the 
incorporation of modified nucleotides into the 3’ OH of broken DNA strands 
due to apoptosis. These modified nucleotides are tagged with a fluorochrome 
or another detectable marker that can be visualized in situ under the 
microscope (189). Since DNA fragmentation can be found in necrosis as 
well, TUNEL assays are used to detect cell death from both apoptosis and 
necrosis (190). Nevertheless, this does not affect our findings, as the aim of 
using TUNEL assay was to detect cell death in general and not distinguish 
apoptotic from necrotic death. 
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3.6 ETHICS 
All the animal experiments conducted in this thesis were granted ethical 
application approval. The animal ethical committee in Gothenburg, Sweden 
approved the animal experiments for papers I, II, and III (approval numbers 
144-12 and 44-15). Lund University’s animal welfare committee approved 
the radioiluminography tests in paper II (M53-11 and M79-13). Ethical 
permit for retrieving human nephrectomized kidney tissue was obtained from 
the regional ethical committee in Gothenburg (R110-98). 
Throughout the experiments, the researchers performing the animal 
experiments kept a strict application of the three R´s of humane animal 
ethical handling (191): replacement, reduction, and refinement. Continuous 
clinical observation of the animals during the experiment time and care 
protocols were documented and supervised by veterinarians and licensed 
animal caretakers at the EBM core facility in Gothenburg. 
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4 RESULTS AND DISCUSSION 
 
4.1 PAPER I: Chronic peritoneal dialysis in uremic, 
anuric rats 
PD is one of two possibilities to dialyze the blood when the kidneys have 
reached end-stage renal failure and RRT is needed. Research on PD function, 
dialysis fluids, and peritoneal function is of high importance since the PD 
method is a great option for patients but is rarely sustainable. With a well-
functioning chronic PD animal model, PD could be further examined in vivo 
and since no such model existed, we intended to develop a new model of 
chronic PD in uremic, anuric rats. 
 
4.1.1 Chemical nephrectomy 
When testing PD models on animals, it is important to mimic the clinical 
setting. This means that the model should be tested in anuric rats, as patients 
undergo PD due to loss of renal function. Animal models of PD have been 
lacking in this aspect, due to the complexity of producing such a model and 
the high dropout rates related to the techniques used (127, 130, 131, 143, 
192). The classical methods of inducing uremia through surgery present 
problems, such as profound effects on the circulation, variation in achieved 
GFR, poor reproducibility, severe trauma, and risk of infection in the animals 
(144-147, 193, 194). Orellanine is known to induce irreversible renal failure 
in humans and rats, as shown in clinical and experimental tests of the toxin, 
without affecting the rest of the body’s organs (114, 120). Orellanine was 
therefore used to induce chemical nephrectomy in our PD model.  
In rats, three different levels of uremia have been defined: mild (serum urea 
between 6.68–13.36 mmol/l), moderate (16.7–33.4 mmol/l), and severe (> 
33.4 mmol/l) (195). In order to determine the dose of orellanine needed to 
render the rats anuric in our experiments, three different doses of orellanine 
were tested (5, 7, and 10 mg/kg) (see methods section). The 5 mg/kg dose of 
orellanine induced severe uremia, with serum urea levels of 46.2 ± 5 mmol/L 
and serum creatinine values at 381.3 ± 23 µmol/L and was therefore chosen 
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as the chemical nephrectomy dose. This dose is in concordance with the LD50 
of orellanine in rats described previously in the literature (4). The dialysate 
urea and creatinine concentrations were higher in the orellanine-treated rats 
than in rats with intact kidneys on the first day of the experiment, reflecting 
severe uremia. The same was true at Day 21 even though the urea and 
creatinine levels were significantly lower due to efficient dialysis. PD 
clearances of both creatinine and urea were nearly the same in all rats and 
reflecting a highly adequate PD treatment. Taken together, these data show 
that using orellanine is an effective way to introduce chemical nephrectomy 
in rats at a bolus dose of 5 mg/kg when given intraperitoneally 2-3 days prior 
to PD. 
 
4.1.2 Efficacy parameters of PD 
Animal models of PD have several challenges; the hardest is keeping the 
animals healthy for a chronic period of time while being anuric when the 
animals require repeated PD cycles for survival. Such a procedure is 
laborious and needs persistent efforts to keep the animals healthy (127, 130, 
131, 192). The rats in our chronic PD model were healthy and gained weight 
during the experiment with a mean arterial blood pressure (MAP) being 
adequate for perfusion in both groups of rats. The weekly urea effective 
clearance (Kt/V) was higher than 3 for both intact kidney and anuric animals 
and over the minimum limit for PD adequacy in man (≥ 2.0) (196). The 
precautions against peritonitis (see Methods section) and the multiple dwells 
played a role in obtaining a stable UF over the PM. Over the experiment 
time, our APD model had a steady ultrafiltration rate close to 20 ml/24h with 
no UFF for any of the rats. This means that neither technique failure nor 
peritonitis were present. Finally, as the animals were awake and only 
anesthetized during catheter implantation, anesthesia did not affect the PM 
ultrafiltration ability through increased lymphatic drainage (197) or altered 
PM permeability (198). 
 
4.1.3 Inflammatory parameters and peritonitis 
Peritonitis poses the greatest risk factor for rendering the PM dysfunctional in 
terms of performing PD (86, 199, 200). After five years on PD, 25% of 
anuric patients need to be transferred to hemodialysis due to peritonitis and 
loss of UF (201, 202). Therefore, several precautions were taken to avoid 
dropouts due to peritonitis in our model (see Methods section). To monitor 
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the inflammatory changes throughout the PD period, dialysate was collected 
from the second cycle on the first and last day of the experiment. Blood 
samples were collected during the autopsy at the end of the experiment. The 
inflammatory response was investigated by quantifying the expression of 
interleukins (IL-1β and IL-6) and growth factors (VEGF and TGF-β) in the 
blood, dialysate, and abdominal tissue. These cytokines are important 
indicators of inflammatory processes, including angiogenesis and fibrosis, 
and will, with time, alter the efficacy of the PM as a dialyzing barrier (203) 
(204). A prominent cytokine found in peritonitis is IL-1β, produced by 
macrophages (205). IL-1β stimulates mesothelial cells to produce IL-8, 
which in turn recruits polymorphonuclear cells to the PM. In rats, IL-6 
elevation is found in active peritonitis and can be used to predict mortality 
due to inflammation (206). A similar study in humans showed that IL-1β and 
IL-6 are valuable predictors of systemic deterioration of patients with 
progressing peritonitis (207). In our experiment, IL-1β and IL-6 did not show 
significant elevations of expression in the peritoneal tissue, in the dialysate 
fluid, or in plasma from rats with chemical nephrectomy, leading to the 
conclusion that the model does not induce inflammation in the rats. Dialysate 
of rats with intact kidneys had higher IL-1β and IL-6 at day one compared to 
the end, due to two rats having levels that were approximately 25-fold higher 
than average. This could be due to these rats having a transient inflammation 
after the implantation of the PD-catheter that resolved before the end of the 
experiment.  
TGF-β induces EMT of mesothelial cells in rodents and humans (208, 209). 
Cells having undergone EMT will induce an inflammatory response by 
producing more VEGF (210). VEGF in the PD setting in both rats and 
humans is known to increase the small solute permeability and the 
subsequent UFF type-1 (211-214). In the literature, peritoneal dialysis with 
hyperosmolar glucose-based PD fluids alone induced increased VEGF and 
TGF-β protein expression in the dialysate fluid of rats undergoing PD (157, 
215). In our experiment, TGF-β expression in tissue and plasma showed no 
significant elevations. VEGF expression in tissue showed a trend of elevation 
in the intact kidney and the anuric rat groups compared to the controls; this 
observation was supported by VEGF in plasma and elevations in the two 
groups compared to the control (undialyzed) animals.  
Pawlaczyk et al. showed that uremia in an acute setting (four days) could 
independently affect the cytokine profiles at the PM barrier (139). In another 
study, independent effects of chronic uremia on the PM were seen in rats 
being bilaterally nephrectomized (140). However, the rats in the latter study 
had invasive nephrectomy and were not on chronic PD and control animals 
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were intact kidney rats. Our study shows that uremia does not have an 
independent effect on any of the tested cytokines over dialysis alone – at least 
not to any significant degree on the biomarkers tested. A possible explanation 
for this could be that repeated dwells with APD over a chronic time 
contributed to resolving the effects of uremic toxins on the PM. 
 
4.1.4 Solute profiles 
Several parameters are used as a standard for testing the quality of PD (216). 
Besides urea and creatinine, we monitored the dialysate (day 1 and day 21) 
and the blood levels (day 21) of sodium, potassium, phosphate, calcium, and 
glucose. Orellanine-nephrectomized rats had higher levels of dialysate 
phosphate, sodium, and potassium on day 1, indicating the expected 
increment in these electrolytes due to the loss of kidney function (217). By 
day 21 of the APD period, and by virtue of the active peritoneal clearance, 
values of sodium and potassium in the PD fluid were similar in both groups. 
Serum levels of sodium and potassium were the same and confirmed the 
dialysate results. On day 21, phosphate levels reached the same levels in both 
dialysate and serum of the tested animals, both being within the normal range 
(1.71–2.68 mmol/L) (218, 219). Meanwhile, dialysate calcium levels 
remained higher in the anuric rats at day 1 and day 21. Renal failure is known 
to cause abnormalities in calcium and phosphate balance (168). 
Unfortunately, no test of the serum calcium profile was available. Glucose 
levels were higher in the rats with intact kidney function, with plasma being 
slightly in the upper range of the reference values (4.7–7.3 mmol/L) for both 
groups. Elevated blood glucose is commonly seen in PD of anuric patients 
with the use of high glucose PDF (169, 220). In general, the electrolytes 
profiles plus the MAP, Kt/V, and weight gain of the animals indicated 
adequacy in the APD system in kidney function in anuric rats.  
This is the first paper to report the results of chronic APD on anuric animals 
with five dwells daily for three weeks. If translated to humans, this would be 
allometrically equivalent to approximately two years on dialysis (148). In 
clinical settings, ESRD patients in need of PD are uremic and will undergo 
treatment for a chronic period of time. Therefore, it is important to resemble 
the clinical setting when investigating PDF or PD quality. Taken together, it 
has been shown that our PD model may be a useful tool for PD research in 
general, and for understanding the microenvironmental physiology and 
pathology of the PM. 
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4.2 PAPER II: Pharmacokinetic properties of the 
nephrotoxin orellanine in rats 
Clinically, mushrooms containing orellanine will induce renal failure 7 to 21 
days after ingestion (5, 221). There have been no reports of the actual 
distribution or the pharmacokinetic profile of orellanine. Whole-body 
distribution and pharmacokinetics studies are important in order to acquire an 
understanding of which organs take up orellanine and the rate it is eliminated. 
 
4.2.1 Radioiluminography 
In order to conduct distribution tests, 3H-labeled orellanine was injected 
intravenously in two groups of rats: one with intact kidney function prior to 
the 3H-labeled orellanine dose, and one group that was chemically 
nephrectomized using a dose of 5 mg/kg of orellanine ip, two days prior to 
the administration of the 3H-labeled orellanine. In both experiments, the 
radioactivity in blood gradually declined over time, from 8.6 nmol-eq/g for 
the single dose experiment at 0.5 h to 4.9, 2.0, 1.7 and 1.3 nmol-eq/g at 1, 2, 
6, 12, and 24 h respectively. A similar pattern was seen in the 
nephrectomized rat experiments with values from 9.0 nmol-eq/g at 0.5 h to 
12, 3.5, and 1.8 for the same time points. The quantitative evaluation of 
orellanine in different organs compared to heart blood in both the intact 
kidney and the nephrectomized rat groups are shown in Figure 5. Note that 
this method, like the beta scintillation, does not separate orellanine from its 
metabolites. Despite this fact, the kidney cortex and the urinary bladder 
showed the highest levels of orellanine at all time points. 
This observation confirmed the distribution and clearance patterns of 
orellanine measured with UPLC-MS/MS and beta scintillation methods (see 
section below). A toxicological study with quantitative measurements of the 
damage to and amounts of orellanine in different organs will largely add to 
the knowledge of the actions of orellanine in the body but is outside the aim 
of this thesis. 
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Figure 5: Tissue to heart blood ratios of the concentration of radioactivity after a single 
intravenous administration of 3H-labeled Orellanine to the male rat (A) and after pre-
treatment (chemical nephrectomy) with unlabeled orellanine (B). 
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4.2.2 The plasma half-life of orellanine 
Orellanine is known for its complicated chromatographic behavior, and its 
thermo- and photo-liability, making it difficult to detect (111, 174, 222). 
Orellanine has been detected in plasma using various methods such as TLC, 
electrophoreses, ESR, HPLC, and LC/MS (3, 174, 223). Herrmann et al. used 
quadrupole time-of-flight mass spectrometry/mass spectrometry (QTOF-
MS/MS) to detect orellanine in mushrooms, mushroom stew, and blood 
samples (112). However, there have been no reports of the measurements of 
the half-life or the elimination of orellanine in plasma. Such measurements 
are important for two reasons. Firstly, the measurement is important for 
diagnostics and clinical management of suspected cases of orellanine 
intoxication. Secondly, we are testing orellanine as a chemical nephrectomy 
tool (paper I of this thesis), and as a potential therapeutic option for 
metastasized ccRCC (paper III). 
In order to investigate the half-life of orellanine, rats were given 5mg/kg of 
orellanine iv, and blood samples were collected 10, 30, 45, 60, 90, 180, and 
360 min after administration. Three groups of rats were used in the 
experiment: one group with intact kidneys, one group with ligated kidneys, 
and one group with ligated kidneys that underwent PD. The half-life of 
orellanine was measured with UPLC-MS/MS and beta scintillation. The mass 
spectrum of orellanine (parent 253.04, fragment ion 236.2) detected by our 
method was in concordance with previously published spectra (176, 222, 
224, 225). Orellanine was cleared from the kidneys with the lowest half-life 
in the intact kidney group (109 min on average) (see Figure 6). The short 
half-life of orellanine is in concordance with clinical experience in humans, 
where orellanine is not detectable in urine two days after exposure (3, 119). 
In animals, it was speculated that orellanine would be cleared from the body 
in less than two to three days (226).  
In our experiment, the group of rats with ligated kidneys had the longest half-
life. The group with ligated kidneys that underwent PD had a lower half-life 
and increased peritoneal clearance of orellanine compared to the group with 
ligated kidneys only (Figure 6), meaning that PD can help eliminate 
orellanine. 3H-labeled orellanine measured with the beta scintillator showed 
higher half-life times in all the rat groups than measurements done with MS 
(Figure 6). The difference could be explained by the fact that the MS only 
measures orellanine, whereas the beta scintillation also picks up signals from 
any metabolites formed in the body. However, in our experiments, it is 
unknown whether these metabolites added to the toxicity of orellanine. Two 
metabolites of orellanine are known. One is produced by reduction of 
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orellanine and is toxic (orellinine), and the other is a product of orellanine 
reduction (orelline) and is nontoxic (223, 227, 228).  
Our UPLC-MS/MC picked up metabolites with peaks at RT 3.5-4.5 min that 
were not present in the reference samples. They had the lowest levels in the 
rats with intact kidney function and highest in the rats with ligated kidneys. 
These metabolites fragmented in the ion source and were detected as 
orellanine (parent 253.04, fragment ion 236.2), which might have led to an 
overestimation of the intact orellanine levels with our UPLC-MS/MS 
method. We speculate that these metabolites can be glucuronides. 
Glucuronidation can result in metabolites having shorter RT than orellanine. 
The conjugation of hydroxyl groups in aromatic systems to glucuronic acid 
can form unstable metabolites in the ion source and can be detected as the 
parent compound (229). A previous paper published in our group showed that 
mono- and di-glucopyranoside are naturally occurring glucosides of 
orellanine in mushrooms and they were eluting with a shorter RT than 
orellanine (112). Acidic environments have shown to hydrolyze these 
metabolites to orellanine. When plasma samples were analyzed again after 
storage in an acidic environment, there was a further increment in orellanine 
levels. If such hydroxylation occurs in plasma, this will lead to an 
overestimated signal of orellanine in the chromatogram. In our setup, we tried 
to change the MS-method parameters to minimize ion-source fragmentation 
of such metabolites, but this led to diminished intensity of these metabolites, 
confirming that they are unstable during the ionization process. A suggestion 
for improvement of our UPLC-MS/MS method would, therefore, be to 
separate these metabolites at baseline, in order for their fragmentation 
products not being mistaken for intact orellanine. Such separation is hard to 
achieve in our setup for two reasons. Firstly, glucuronides are highly 
hydrophilic, and therefore tend to co-elute near the peak of the solvent they 
are in. Secondly, we speculate more than one glucuronide may be present in 
the plasma samples, leading to further complication of the chromatographic 
separation (230).  
Nevertheless, UPLC-MS/MS detected orellanine levels as low as 0.04 µg/ml. 
Doses given with therapeutic purpose for ccRCC in rats were 10 mg/L in 
PDF, which counts for 10 µg/ml. Thus, our UPLC-MS/MS is suitable for 
measuring the future therapeutic window of orellanine. 
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Figure 6: Plasma half-life of intact and 3H-orellanine in intact kidneys, ligated kidneys, and 
ligated kidneys in rats on PD. 
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4.3 PAPER III: ORELLANINE SPECIFICALLY 
TARGETS RENAL CLEAR CELL 
CARCINOMA 
Seventy percent of RCC are ccRCC, notorious for their metastatic frequency 
and high resistance to conventional cancer therapies (99, 231). Emerging 
therapies directed against specific molecular targets are not curative in 
ccRCC (98). We wanted to investigate the toxicity of orellanine in tubular 
and cancer cells. Since ccRCC originates from proximal tubular cells, we 
hypothesized that if orellanine is toxic to the tubular cells, it may also be 
toxic to the cells in the metastases of ccRCC. 
 
4.3.1 In vitro tests 
Although the mechanism of orellanine toxicity is yet not fully understood, the 
outcome of toxicity and selectiveness for PCT are well described (4, 109, 
122, 221, 226, 232). The results in our study confirmed the findings in the 
literature: orellanine selectively and irreversibly damages HTEC while 
having a minimal and reversible effect on other tested cell lines, such as 
HUVEC, HPEG2, and MDA cells. Once orellanine was removed from the 
cultured cells, all cell lines recovered and continued to grow, except for 
HTEC. This is in line with the orellanine poisoning pattern, in which after the 
accidental intake of the mushroom, no other organ damage except for kidney 
failure has been observed in patients (5, 221). When investigating the effect 
of orellanine on different ccRCC primary cell lines (786-O, SKRC-7, SKRC-
10, SKRC-21, 087), and metastatic cell lines (SKRC-17, SKRC-52), 
orellanine showed a dose-dependent effect with decreased viability of the 
cells. This effect increased with longer incubation times but not by repeated 
low dosing, which could be useful in the future planning of dosage regimens 
in treating metastasized ccRCC. Earlier studies of orellanine’s mechanisms 
for cell damage have indicated ROS activation as a part of the mechanism (4) 
and our data confirmed these findings. Orellanine-treated cells showed a 
decreased ability to shift to the glycolysis pathway for generating energy 
once the mitochondrial pathway was shut down. Orellanine damaged the 
cellular metabolism through an increase in proton leakage, a decrease in ATP 
synthesis, and a global decrease in the respiratory capacity (basal, maximum, 
and spare capacity). 
Apoptosis of the cells was investigated by studying the activation of cleaved 
caspase-3, as well as both the intrinsic (caspase-9) and the extrinsic (caspase-
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8) pathways. Apoptosis and necrosis were evident in the aggressive and 
resistant metastatic ccRCC cell lines SKRC-17 and SKRC-52 after orellanine 
treatment. This was shown by western blot results and confirmed with 
activity assay results. Flow cytometry analysis of annexin V and PI staining 
of treated metastatic ccRCC cells showed a shift toward necrosis and 
apoptosis after 72 hours of cell incubation with orellanine. Western blot 
analyses of the phosphorylated protein kinase B, also known as AKT, 
showed decreased levels. AKT is a downstream effector of signaling 
pathways involved in glucose metabolism, apoptosis, cell proliferation, 
transcription, and cell migration. The decreased phosphorylation of AKT 
indicated a loss of ability to inactivate apoptotic pathways in treated cells. 
Extracellularly regulated kinase-1 and -2 (ERK1 and 2) are important 
proteins for cell survival functions, including the regulation of meiosis, 
mitosis, and post mitosis in differentiated cells. The expression of both ERK1 
and 2 was found to be down-regulated after orellanine treatment. Proteomic 
analyses showed a battery of up-regulated apoptosis and necrosis activator 
proteins as well as loss of protein synthesis, cell migration, and protein 
transcription catalyzing proteins. Taken together, this shows that orellanine 
toxicity is not limited to proximal tubular cells but affects tumors and 
metastasis originating from these cells. 
 
4.3.2 A xenograft rat model for metastasized ccRCC 
Since our in vitro experiments showed the potential of orellanine to damage 
ccRCC-derived cells, we investigated the effect in vivo using a xenograft 
model for metastasized ccRCC in rats. In order to further immunosuppress 
athymic rats, they were subjected to a radiation dose of 4 Gray before 
xenograft implantation (details in the methods section). This led to the 
suppression of B-cell function without affecting the rats’ general health in 
terms of appetite and growth. SKRC-17 cells were injected into the rats 
subcutaneously and allowed to form a tumor. When the cell mass had turned 
into a solid tumor (approximately after seven to eight days), intraperitoneal 
dosing of orellanine in PDF (10 mg/L) was administered with each dwell. 
Orellanine levels in the rats’ blood reached a steady state after the first day. 
Since orellanine renders the rats anuric, the kidney function during treatment 
with orellanine was replaced using the APD system developed in paper I. 
Plasma levels of creatinine and urea raised to uremic levels with polyuria at 
day two and three, and anuria at day six. Thirty minutes after starting APD, 
the dialysate creatinine and urea levels approached those in plasma, 
indicating an efficient PD. The APD system functioned in replacing the 
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kidney function in all orellanine-treated rats. Eight days after the implantation 
of the SKRC-17 cell mass, 10 mg/L orellanine given for eight days shrunk 
the tumors and increased necrosis in the tumors significantly compared to 
untreated tumors. When given at day 4 after implantation of the ccRCC cell 
mass, orellanine at 10 mg/L for five days or 20 mg/L for three days led to an 
even more successful outcome. Extreme damage to the tumor mass was seen 
and a complete resolution of the tumor cell mass in two of the treated rats. 
The tumor masses collected from the treated rats were morphologically dark, 
soft, significantly lighter in weight, and 90% smaller in mass than the control 
rat tumors (Figure 7). Positive TUNEL staining was observed in 23 ± 7% in 
the 10mg/L dose group and 24 ± 5% in the 20 mg/L dose group. It is 
furthermore worth mentioning that gross morphological evaluation of the 
other organs by an independent pathologist revealed no damage on the brain, 
lung, heart, liver, spleen, intestine, or skeletal muscle tissue from the treated 
rats. 
These results confirm that orellanine is highly toxic to human ccRCC cells 
even after metastases. 
 
Figure 7: Representative pictures of matching SKRC-17 tumors from untreated (A) and 
orellanine-treated rats 24 h after treatment (B). Note: treated tumors are purple-colored and 
small, while untreated control tumors are hard, pink, and considerably larger.  
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5 CONCLUSIONS 
 
Paper I 
Orellanine can be considered as a chemical nephrectomy tool to induce 
anuria in experimental PD models. Our new APD method is efficient in 
maintaining anuric rats healthy and with normal homeostasis over a chronic 
period of time. Uremia did not have an independent effect on the dialysis 
procedure itself, did not induce peritonitis or PM damage, and did not alter 
the electrolyte profiles of the treated animals compared to rats undergoing 
APD with intact kidneys. The APD model developed is reproducible, can be 
applied to other animals, and may be useful in both PD research and in 
understanding the physiology and pathology of the PM in ESRD. 
Paper II 
Orellanine injected intravenously in rats in vivo is eliminated via the kidneys. 
The kidney cortex and the urinary bladder receive the majority of orellanine 
and its metabolites after administration. Orellanine forms metabolites in the 
blood that are eliminated with the same pattern as the intact parent molecule, 
albeit at a slower pace. PD and/or urinary excretion clear orellanine and its 
metabolites from the body.  
Paper III 
Orellanine selectively targets HTEC and ccRCC primary and metastasized 
cell lines both in vitro and in vivo in ccRCC bearing rats. Orellanine 
interferes with the energy metabolism, protein synthesis, and cellular growth, 
leading to decreased survival and induction of apoptosis and necrosis in 
treated cells. Orellanine, therefore, holds a promising capacity to be used as a 
potential therapeutic option for patients with late stage, metastasized ccRCC. 
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6 FUTURE PERSPECTIVES 
This thesis examined the nephrotoxic and therapeutic effects of orellanine, 
highlighting the use of orellanine as a nephrectomy tool for PD research, as 
well as a therapeutic option for patients with metastasized ccRCC. Although 
this thesis has added to our understanding of orellanine and uses of the toxin, 
there is still more that needs to be investigated. Several challenges are ahead 
of us in order to take full advantage of the therapeutic potential of this 
nephrotoxin. Here follows some suggestions for future studies that would be 
valuable additives to our understanding of the subject. 
  
6.1 TRANSPORTER STUDIES 
Both literature and experiments in this thesis indicate that orellanine is 
selectively taken up by PCT cells, but the exact mechanism behind how 
orellanine enters the PCT cells is still unknown. Therefore, it is of great 
importance to study the uptake of orellanine into tubular and renal cancer 
cells. Since PCT are highly active cells with many different transporters 
involved in reuptake of filtered solutes from primary urine to circulation, it is 
difficult to test all transporters. One way to approach the large number of 
transporters and proteins important for orellanine toxicity is by utilizing a 
CRISPR-Cas9 library (233). A clustered regularly interspaced short 
palindromic repeats (CRISPR) library consists of approximately forty 
thousand guided genes (gRNAs) that can be incorporated into cells using 
viral transfection. These gRNAs will then connect to the CRISPR-associated 
9 (Cas9) enzyme and create a complex that will target DNA and cleave a 
certain gene coding for a protein in the cell. If incorporated into orellanine 
sensitive cells, and the gene knocked out codes for the protein responsible for 
orellanine uptake, the hypothesis is that these cells will survive orellanine 
treatment. Surviving cells can, via deep sequencing, be screened for the 
knocked gene responsible for the cellular resistance to orellanine treatment. 
Possible transporters for orellanine will then need to be evaluated both in 
vitro and in vivo as the toxic effect of orellanine should be abolished by 
blocking the selective uptake mechanism. Finding the transporter and the 
signaling pathways for orellanine action will provide knowledge of its 
specific mechanism of action. 
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6.2 TOXICOLOGY STUDIES 
Whether researching the use of orellanine in PD or as a drug against 
metastasized ccRCC, it is vital to evaluate the possible side effects of 
orellanine. Patients ingesting orellanine by mistake have not expressed any 
signs of organ damage other than kidney failure (5), but the amounts ingested 
are difficult to determine. Our gross pathological evaluation of the orellanine-
treated rats confirmed the specific renal toxicity as well. Only one study in 
literature on mice has shown hepatic and splenic damage plus kidney damage 
(225). The only way to evaluate and quantify the potential damage is by 
running a toxicological in vivo test.  Organ damage should be evaluated in 
combination with quantitative tissue LC/MS to analyze traces of orellanine in 
all the organs of the body. This will give a more complete picture of the 
elimination and toxicity of orellanine and will complement the distribution 
tests in paper II. 
 
6.3 COMPUTATIONAL MODELING OF THE 
PERITONEAL MEMBRANE USING THE 
THREE-PORE MODEL 
In order to further examine the PD model developed in paper I, peritoneal 
dialysis capacity can be measured in terms of the transperitoneal passage of 
water and solutes during PD with the three-pore model (TPM) described by 
Rippe and Haraldsson (234, 235). The TPM describes the transport of water 
and solutes from the capillaries in the peritoneum from three different pore 
sizes: Large (diameter 10–20 nm), small (4–6 nm), and ultra-small pores 
(mainly aquaporin-1, 0.4–0.6 nm). This technology is validated with clinical 
observations (236). With the aid of this method, a standardized measurement 
of the nutritional status, UF, residual renal function, total peritoneal 
clearance, and PM transport can be achieved. To analyze the properties of the 
peritoneum, we will use MathCad Prime 4.0 and Delphi Professional 10.2 
Tokyo. 
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6.4 CHRONIC EFFECTS OF ORELLANINE ON 
METASTASIZED CCRCC 
In paper III, we explored the effect of orellanine on metastasized ccRCC in 
an in vivo rat model. The treatment period was not more than eight days. This 
was due to the complexity of protecting immunocompromised anuric animals 
from infection after exposure to surgery and APD tubing. Several 
experimental sets needed to be terminated ahead of experimental study plans 
due to confirmed infections from intestinal Enterococci. Since orellanine had 
a dramatic effect on the metastasized SKRC-17 tumor masses, we 
hypothesize that a longer period of treatment will further increase the 
apoptosis and necrosis of these tumors and further reduce viability of the 
tumor mass. A xenograft mouse model could be utilized, in which instead of 
PD, the mice will be terminated before signs of uremia start. The implanted 
tumors will then be moved to the next mouse. Repeated xenograft 
transplantation will show the effect of orellanine chronically. An example of 
how such an experiment could be set up is shown in Figure 8. 
 
 
Figure 8:  The working plan of a xenograft mouse model of ccRCC allowing for a longer 
exposure of orellanine. 
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